logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

China Building Materials (03323.HK): Xue Zhongmin resigns as vice president.

date
26/09/2025
The China Building Materials (03323.HK) announced that Mr. Xue Zhongmin has resigned as the Vice President of the company due to work adjustment, effective from September 26, 2025.
Latest
1 m ago
China Medical Technology (08156.HK) announces annual performance. The company's owners are expected to incur a loss of approximately HK$900,000, a significant decrease of about 95% year on year.
2 m ago
WTT China Grand Slam: All 7 members of the Chinese national team won their qualification matches the next day.
3 m ago
According to documents from the Hong Kong Stock Exchange, Jiangsu Slender West Lake Cultural Tourism Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange.
3 m ago
WTI crude oil futures rose 2.00% intraday, now trading at $66.28 per barrel.
3 m ago
Pharmaceutical company Crinetics Pharmaceuticals soared 26.6% in early trading, receiving approval from the US FDA for its treatment drug Palsonify for acromegaly. The approval was based on successful phase three trials, and the product is scheduled to be launched in early October. This marks an important milestone for Crinetics in the field of rare disease treatment.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.